Mirum Pharmaceuticals Business Summary

Mirum Pharmaceuticals, Inc. (MIRM) is a commercial-stage biopharmaceutical company that generates revenue through the sale of targeted therapies for rare cholestatic and metabolic liver diseases. Its primary business segments are centered on its flagship product, LIVMARLI (maralixibat), approved for Alagille syndrome and progressive familial intrahepatic cholestasis, and its bile acid portfolio, which includes CHOLBAM and the recently FDA-approved CTEXLI (chenodiol) for cerebrotendinous xanthomatosis. Following the January 2026 acquisition of Bluejay Therapeutics, Mirum has expanded its clinical segment into the chronic hepatitis delta virus (HDV) market with the late-stage candidate brelovitug. The company operates as a leader in the niche hepatology space, competing directly with Ipsen (Bylvay), Ultragenyx, and Albireo Pharma, while maintaining a competitive advantage through its specialized commercial infrastructure and a diversified pipeline targeting primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC). Mirum was founded in 2018 by a team of industry veterans including CEO Christopher Peetz, Chairman Michael Grey, and Niall O’Donnell, all of whom possess significant pedigrees from Frazier Healthcare Partners and Tobira Therapeutics. The current executive leadership team includes Eric Bjerkholt as Chief Financial Officer, Peter Radovich as President and Chief Operating Officer, Dr. Hassan Javanbakht as Chief Scientific Officer, and Dr. Joanne Quan as Chief Medical Officer. The company is backed by prominent institutional investors such as Frazier Life Sciences, New Enterprise Associates (NEA), and Deerfield Management. Its board of directors features notable industry figures including Laura Brege, Patrick Heron, and Timothy Walbert, the former CEO of Horizon Therapeutics, providing deep strategic expertise in rare disease commercialization.